The tumor-promoting activities of the inflammatory mediators CCL2 & CCL5 and TNFα & IL-1β in breast cancer are not fully overlapping (references above), therefore their coordinated expression may eventually provide advantage to the developing and metastasizing tumor. The gene discussed is CCL2; the disease is breast cancer.